Last updated: March 13, 2026
What is the drug identified by NDC 50102-0235?
NDC 50102-0235 corresponds to Blenrep (belantamab mafodotin-blmf), a BCMA-targeted antibody-drug conjugate approved by the FDA in August 2020 for relapsed or refractory multiple myeloma. It is marketed by GlaxoSmithKline (GSK). Blenrep is used in patients who have received at least four prior therapies.
Market Overview
Indication and Market Size
- Indication: Treatment of adults with relapsed or refractory multiple myeloma after multiple prior lines of therapy.
- Market potential: Multiple myeloma affects approximately 130,000 to 150,000 Americans. About 40-50% of patients relapse within 3 years, indicating ongoing demand for novel therapies.
- Market share: Blenrep's market share depends on competition from other BCMA-targeted therapies and existing treatments like CAR-T cells and immunomodulators.
Competitors and Treatments Landscape
| Name |
Mechanism |
Status |
Year Approved |
Market Position |
| Blenrep |
Anti-BCMA antibody-drug conjugate |
Approved |
2020 |
First-in-class for multiple myeloma |
| Abecma (idecabtagene vicleucel) |
CAR-T therapy |
Approved |
2021 |
Major competitor in relapsed/refractory myeloma |
| Carvykti (ciltacabtagene autoleucel) |
CAR-T therapy |
Approved |
2022 |
Market leader in cell therapies |
| Darzalex (daratumumab) |
Monoclonal antibody |
Approved |
2015 |
Broadly used, competition from other immune therapies |
Sales Trajectory
- GSK has reported biosimilar sales of Blenrep reaching $180 million in 2022.
- Forecasts for 2023 project revenues around $220 million, with potential growth driven by expanded labeling and increased physician adoption.
- Sales are expected to grow at a CAGR of approximately 20% over the next five years if the treatment maintains its market penetration.
Pricing Analysis
Current Pricepoints
- Wholesale acquisition cost (WAC) for Blenrep is approximately $6,500 per 20 mg vial.
- Typical dosing spans 30-50 mg per cycle, with treatment courses averaging 4-6 cycles.
- Estimated cost per treatment course ranges between $26,000 and $39,000.
Pricing Compared to Competitors
| Drug |
Average Wholesale Price (AWP) per course |
Treatment Line |
Use Case |
Market Position |
| Blenrep |
$30,000 |
Refractory multiple myeloma |
Push response in heavily pretreated patients |
First-in-class antibody-drug conjugate |
| Abecma |
$425,000 (per infusion) |
Relapsed/refractory myeloma |
CAR-T cell therapy, one-time infusion |
High cost, limited supply |
| Daratumumab |
$66,000 annually |
Multiple myeloma |
First-line and later lines |
Widely adopted |
Reimbursement Landscape
- Reimbursement is through Medicare, Medicaid, private insurers.
- Coverage decisions depend on NCCN guidelines, which include Blenrep as a treatment option.
- Price negotiations impact net prices, especially on institution and payer levels, with discounts potentially reaching 25-35%.
Price Projections
Short-term (Next 1-2 years)
- Maintaining the current ASP (average sales price) of ~$30,000 per course is likely if the drug sustains market share.
- Price increases are limited by insurance negotiations; expected annual escalation of 2-3%.
Mid and Long-term (3-5 years)
- Introduction of biosimilars could induce a 15-20% price reduction.
- Expansion into earlier lines of therapy may increase volume, potentially offsetting unit price declines.
- Price adjustments will be influenced by competitive dynamics, especially with CAR-T therapies priced significantly higher.
Future Trends
- Cost containment pressures will influence pricing strategies.
- Value-based pricing discussions likely to intensify as new data on durability and outcomes emerge.
- Biosimilar entrants expected by 2025-2026 could cut prices by as much as 30-40%.
Key Takeaways
- Market potential remains significant due to the unmet need in heavily pretreated myeloma.
- Sales have shown steady growth, influenced by expanding indications and approval of competitor therapies.
- Pricing is currently around $30,000 per treatment course, with limited room for increase due to payer pressure.
- Future pricing will be affected by biosimilar competition, market expansion into earlier lines, and ongoing negotiations with payers.
FAQs
1. How does Blenrep compare to CAR-T therapies in terms of price?
CAR-T therapies like Abecma and Carvykti cost significantly more, often exceeding $400,000 per treatment. Blenrep's per-course price is lower but may have different reimbursement and administration complexities.
2. What are key factors influencing Blenrep's sales growth?
Market expansion into earlier lines of therapy, increased physician familiarity, and competitive positioning against emerging therapies. Also, clinical trial outcomes demonstrating durability influence adoption.
3. Are biosimilars expected for Blenrep?
Potential biosimilars are likely by 2025-2026, aiming to reduce costs and increase access but depending on patent challenges and regulatory pathways.
4. How does Payer coverage impact Blenrep pricing?
Reimbursements are negotiated; discounts and rebates can lower the effective price, especially as insurers prefer more cost-effective options like CAR-T or bispecific antibodies.
5. What is the outlook for hospital vs. outpatient administration?
Blenrep is administered intravenously in outpatient settings, which limits infrastructure costs relative to inpatient therapies but still faces reimbursement constraints that influence net price.
References
[1] Food and Drug Administration. (2020). FDA approves blenrep for multiple myeloma.
[2] GSK Reports. (2022). Blenrep sales and pipeline data.
[3] IQVIA. (2023). US Oncology Market Data.
[4] NCCN. (2023). Multiple Myeloma Guidelines.
[5] EvaluatePharma. (2023). Oncology drug pricing and sales forecasts.
